<code id='831D87280C'></code><style id='831D87280C'></style>
    • <acronym id='831D87280C'></acronym>
      <center id='831D87280C'><center id='831D87280C'><tfoot id='831D87280C'></tfoot></center><abbr id='831D87280C'><dir id='831D87280C'><tfoot id='831D87280C'></tfoot><noframes id='831D87280C'>

    • <optgroup id='831D87280C'><strike id='831D87280C'><sup id='831D87280C'></sup></strike><code id='831D87280C'></code></optgroup>
        1. <b id='831D87280C'><label id='831D87280C'><select id='831D87280C'><dt id='831D87280C'><span id='831D87280C'></span></dt></select></label></b><u id='831D87280C'></u>
          <i id='831D87280C'><strike id='831D87280C'><tt id='831D87280C'><pre id='831D87280C'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:entertainment    Page View:964
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In